{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:26:10Z","timestamp":1760077570311,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immunotherapy with immune checkpoint inhibitors is one of the main therapies for advanced melanoma. Nevertheless, albeit remarkable, immunotherapy results are still unsatisfactory as more than half of patients progress, and resistance to treatment still has a dramatic impact on clinical outcomes. Local treatments such as radiotherapy or electrochemotherapy (ECT), in addition to local control with palliative intent, have been shown to release tumoral neoantigens that can stimulate a robust systemic antitumor immune response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>We report the case of a patient with multiple nodular melanoma lesions of the scalp initially treated with local ECT. Soon after the procedure, multiple new lesions appeared close to the treated ones, therefore the patient started a systemic treatment with the anti-PD-1 nivolumab. The lesions of the scalp did not respond to immunotherapy, presenting a loco-regional spreading. To control the bleeding and painful lesions, we performed a second ECT, while continuing systemic immunotherapy. The treated lesions responded to the second procedure, while the other lesions continued progressing in number and dimension. Unexpectedly, after 2 months from the second ECT, the patient presented a progressive shrinkage of both treated and untreated lesions until complete remission. Concomitantly, he developed immune-related adverse events including grade 4 thyroid toxicity, grade 2 vitiligo-like depigmentation and grade 2 pemphigoid. At present, after 18 months from the first ECT and 14 months from the starting of anti-PD-1 immunotherapy, the patient is in good clinical condition and complete remission of disease still persists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case highlights the potential role of ECT in increasing tumor immunogenicity and consequently in inducing a powerful immune response overcoming primary resistance to checkpoint inhibitor immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.742666","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T04:56:16Z","timestamp":1631768176000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp"],"prefix":"10.3389","volume":"11","author":[{"given":"Davide","family":"Quaresmini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Di Lauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Fucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabino","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"De Risi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Monica","family":"Sciacovelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Albano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Achille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Montepara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabino","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes With Dabrafenib Plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival With Ipilimumab in Patients With Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12446","article-title":"Tumour-Associated Antigens and Their Anti-Cancer Applications","volume":"26","author":"Liu","year":"2016","journal-title":"Eur J Cancer Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101474","article-title":"Radiotherapy: An Immune Response Modifier for Immuno-Oncology","volume":"16","author":"De Martino","year":"2021","journal-title":"Semin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next Generation of Immune Checkpoint Inhibitors and Beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic Correlates of the Abscopal Effect in a Patient With Melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.615697","article-title":"MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy","volume":"10","author":"H\u00f6rner-Rieber","year":"2021","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.06.399","article-title":"Treatment Efficacy With Electrochemotherapy: A Multi-Institutional Prospective Observational Study on 376 Patients With Superficial Tumors","volume":"42","author":"Campana","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"24653","DOI":"10.1002\/jso.24287","article-title":"Local Treatment With Electrochemotherapy of Superficial Angiosarcomas: Efficacy and Safety Results From a Multi-Institutional Retrospective Study","volume":"114","author":"Guida","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0462-0","article-title":"Tumor Destruction Using Electrochemotherapy Followed by CpG Oligodeoxynucleotide Injection Induces Distant Tumor Responses","volume":"57","author":"Roux","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-016-9814-x","article-title":"CD4 + FOXP3 + T Regulatory Cells Decrease and CD3 + CD8 + T Cells Recruitment in TILs From Melanoma Metastases After Electrochemotherapy","volume":"33","author":"Di Gennaro","year":"2016","journal-title":"Clin Exp Metastasis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10585-012-9505-1","article-title":"Dendritic Cells Recruitment in Melanoma Metastasis Treated by Electrochemotherapy","volume":"30","author":"Gerlini","year":"2013","journal-title":"Clin Exp Metastasis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-014-1462-x","article-title":"Electrochemotherapy for the Management of Melanoma Skin Metastasis: A Review of the Literature and Possible Combinations With Immunotherapy","volume":"306","author":"Queirolo","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14314","article-title":"The Use of Electrochemotherapy in Combination With Immunotherapy in the Treatment of Metastatic Melanoma: A Focused Review","volume":"58","author":"Goggins","year":"2019","journal-title":"Int J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.3390\/cancers12102781","article-title":"Boosting the Immune Response With the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck","volume":"12","author":"Longo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/vaccines8030537","article-title":"Electroporation as the Immunotherapy Strategy for Cancer in Veterinary Medicine: State of the Art in Latin America","volume":"8","author":"Maglietti","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2015.2522","article-title":"Complete Regression of Melanoma Skin Metastases After Electrochemotherapy Plus Ipilimumab Treatment: An Unusual Clinical Presentation","volume":"25","author":"Brizio","year":"2015","journal-title":"Eur J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1008842","article-title":"Assessing a Novel Immuno-Oncology-Based Combination Therapy: Ipilimumab Plus Electrochemotherapy","volume":"4","author":"Mozzillo","year":"2015","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1856-z","article-title":"Immune Checkpoint Blockade With Concurrent Electrochemotherapy in Advanced Melanoma: A Retrospective Multicenter Analysis","volume":"65","author":"Heppt","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000580","article-title":"Electrochemotherapy With Anti-PD-1 Treatment Induced Durable Complete Response in Heavily Pretreated Metastatic Melanoma Patient","volume":"29","author":"Karaca","year":"2017","journal-title":"Anticancer Drugs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1454602","article-title":"Updated Standard Operating Procedures for Electrochemotherapy of Cutaneous Tumours and Skin Metastases","volume":"57","author":"Gehl","year":"2018","journal-title":"Acta Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/cancers11101559","article-title":"The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma","volume":"11","author":"Guida","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100064","article-title":"Immune Checkpoint Inhibitor Associated Vitiligo and its Impact on Survival in Patients With Metastatic Melanoma: An Italian Melanoma Intergroup Study","volume":"6","author":"Guida","year":"2021","journal-title":"ESMO Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.05.055","article-title":"Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio in Melanoma Patients: A Meta-Analysis","volume":"484","author":"Zhan","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2281","article-title":"Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Breast Cancer Patients: An Updated Meta-Analysis of 17079 Individuals","volume":"8","author":"Guo","year":"2019","journal-title":"Cancer Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cncr.32506","article-title":"High Neutrophil-to-Lymphocyte Ratio (NLR) Is Associated With Treatment Failure and Death in Patients Who Have Melanoma Treated With PD-1 Inhibitor Monotherapy","volume":"126","author":"Bartlett","year":"2020","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01116","article-title":"Prognostic Value of the Platelet-to-Lymphocyte Ratio in Patients With Melanoma: A Meta-Analysis","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.742666\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T04:56:19Z","timestamp":1631768179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.742666\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":28,"alternative-id":["10.3389\/fonc.2021.742666"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.742666","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"article-number":"742666"}}